Plasma miRNAs and the risk of cancer: Data mining model in lung cancer

Author:

Duan Xiaoran1,Huang Tao2,Feng Xiaolei3,Qu Xiaoping4,Ge Minghui4,Yan Linlin4,Guo Hao4,Liu Xiaohua3,Ding Mingcui3,Wang Pengpeng3,Yang Yongli3,Wang Wei3,Zhao Jie1

Affiliation:

1. The First Affiliated Hospital of Zhengzhou University, Zhengzhou University

2. Huanghe Science and Technology University

3. Zhengzhou University

4. Jiangsu Simcere Diagnostics Co., Ltd

Abstract

AbstractData mining(DM) has been widely used in researching the auxiliary diagnosis of cancer. Circulating miRNAs are related to the occurrence and development of various cancer types. For this reason, they have the potential to be used as biomarkers for early tumor diagnosis. Previously, we found that SVM model combined with plasma miRNAs biomarkers could be a method for lung cancer prediction; However, it still has some limitations. So this study further enlarges the analysis to other DM techniques, and explores more accurate methods for auxiliary diagnosis of lung cancer. Univariate analysis showed the differences had statistical significance in the smoking, fever, chest tightness or pain, cough, bloody phlegm, haemoptysis, and 10 plasma miRNAs (miR-21, miR-20a, miR-210, miR-145, miR-126, miR-223, miR-197, miR-30a, miR-30d, and miR-25) between the lung cancer group and normal control group (P < 0.05); Logistic regression analysis showed that fever, chest pain or tightness, cough, miR-21, and miR-223 could be considered as indicators of the presence of cancer (P < 0.05). According to the univariate and multivariate analysis results, two sets of models were constructed using data mining models. The results showed that the sensitivity was 88.6%, the specificity reached 86.7%, the accuracy value was also the highest, and AUC was 0.877 for the GBDT (Gradient Boosting Decision Tree) 16-model, indicating that its predictive effect was the best. Conclusively, this study was to further explore the high accuracy data mining model of lung cancer prediction using plasma miRNAs.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;Cancer J Clin,2021

2. Hesitancy around low-dose CT screening for lung cancer;Dickson JL;Annals of oncology: official journal of the European Society for Medical Oncology,2022

3. Schult TA, Lauer MJ, Berker Y, Cardoso MR, Vandergrift LA, Habbel P, Nowak J, Taupitz M, Aryee M, Mino-Kenudson MA et al. Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics.Proceedings of the National Academy of Sciences of the United States of America2021, 118(51).

4. Hussain S, Tulsyan S, Dar SA, Sisodiya S, Abiha U, Kumar R, Mishra BN, Haque S. Role of epigenetics in carcinogenesis: Recent advancements in anticancer therapy.Seminars in cancer biology2021.

5. Zou R, Loke SY, Tang YC, Too HP, Zhou L, Lee ASG, Hartman M. Development and validation of a circulating microRNA panel for the early detection of breast cancer.British journal of cancer2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3